{
 "id": "type-2-diabetes",
 "name": "Type 2 diabetes",
 "aliases": [
  "Type 2 Diabetes",
  "Type 2 diabetes (T2DM)"
 ],
 "acronyms": [
  "T2DM"
 ],
 "bodySystem": "endocrine",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 3
 },
 "funds": [
  {
   "fund": "Type 2 Diabetes",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Type 2 diabetes (T2DM)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 2000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "fund": "Type 2 diabetes (T2DM) health equity",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 2000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "DAPAGLIFLOZIN",
   "pages": [
    {
     "brand": "Farxiga",
     "url": "https://omnirx.org/negotiated-drugs/farxiga"
    }
   ],
   "labelSentence": "As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2201f90c94-71cb-4a1f-81ff-8004b850529b%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Farxiga Savings (via AstraZeneca)",
     "url": "https://omnirx.org/assistance/farxiga-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": false,
     "note": null,
     "listKind": "Important Program Updates page: product additions and removals only (not the full list)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 183.33,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "DULAGLUTIDE",
   "pages": [
    {
     "brand": "Trulicity",
     "url": "https://omnirx.org/negotiated-drugs/trulicity"
    }
   ],
   "labelSentence": "As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220a4716d0-9c9c-4bc3-a8f1-6784599aae89%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Trulicity Savings (via Lilly)",
     "url": "https://omnirx.org/assistance/trulicity-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Lilly Cares",
     "url": "https://omnirx.org/assistance/lilly-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "the page states new applications are once again being accepted and no longer require a medical exception request",
     "listKind": "Available Medications: list of all products",
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "EMPAGLIFLOZIN",
   "pages": [
    {
     "brand": "Jardiance",
     "url": "https://omnirx.org/negotiated-drugs/jardiance"
    }
   ],
   "labelSentence": "... as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221782b947-4a72-4feb-a488-1469d9af82bd%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Jardiance Savings (via Boehringer Ingelheim/Lilly)",
     "url": "https://omnirx.org/assistance/jardiance-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 202.33,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "LINAGLIPTIN",
   "pages": [
    {
     "brand": "Tradjenta",
     "url": "https://omnirx.org/negotiated-drugs/tradjenta"
    }
   ],
   "labelSentence": "TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22b1da67d4-51e0-41b7-9fe1-7f38c0d1baa1%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 78,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "METFORMIN; SITAGLIPTIN",
   "pages": [
    {
     "brand": "Janumet",
     "url": "https://omnirx.org/negotiated-drugs/janumet"
    }
   ],
   "labelSentence": "... ion of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220098dec4-f0e5-45d5-8aa4-5d0faf9ab142%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Merck Patient Assistance Program",
     "url": "https://omnirx.org/assistance/merck-helps",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Products: participating products",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 80,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "SEMAGLUTIDE",
   "pages": [
    {
     "brand": "Ozempic",
     "url": "https://omnirx.org/negotiated-drugs/ozempic"
    }
   ],
   "labelSentence": "... as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2242bdd912-2393-44c4-b7e0-47672ca28991%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Ozempic Savings (via NovoCare)",
     "url": "https://omnirx.org/assistance/ozempic-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Novo Nordisk PAP (NovoCare)",
     "url": "https://omnirx.org/assistance/novo-nordisk-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "0.5 mg, 1 mg, or 2 mg",
     "listKind": "Available Products (PAP product list PDF)",
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 274,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "SITAGLIPTIN",
   "pages": [
    {
     "brand": "Januvia",
     "url": "https://omnirx.org/negotiated-drugs/januvia"
    }
   ],
   "labelSentence": "JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22194c3718-5eb5-4cf5-85d0-2bb1ed8293b8%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Merck Patient Assistance Program",
     "url": "https://omnirx.org/assistance/merck-helps",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Products: participating products",
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 116.06,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Canagliflozin",
   "pages": [
    {
     "brand": "Invokana",
     "url": "https://omnirx.org/medicines/invokana"
    }
   ],
   "labelSentence": "... as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%225f76e16f-0c24-454a-81af-4080b312c940%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Empagliflozin/Linagliptin",
   "pages": [
    {
     "brand": "Glyxambi",
     "url": "https://omnirx.org/medicines/glyxambi"
    }
   ],
   "labelSentence": "GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22ddbab689-f76c-488c-9613-4168d41dd730%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Empagliflozin/Metformin HCl",
   "pages": [
    {
     "brand": "Synjardy XR",
     "url": "https://omnirx.org/medicines/synjardy-xr"
    },
    {
     "brand": "Synjardy",
     "url": "https://omnirx.org/medicines/synjardy"
    }
   ],
   "labelSentence": "... nd metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220fdd0255-0055-65f3-b2c0-db8fbb87beae%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Boehringer Ingelheim Cares Foundation",
     "url": "https://omnirx.org/assistance/boehringer-ingelheim-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Finerenone",
   "pages": [
    {
     "brand": "Kerendia",
     "url": "https://omnirx.org/medicines/kerendia"
    }
   ],
   "labelSentence": "FR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22fc726765-5d5a-4d6e-b037-b847bda9fb7c%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Bayer US Patient Assistance Foundation",
     "url": "https://www.patientassistance.bayer.us/en/about/bayer-products",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Bayer prescription medicines included in the program",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Insulin Glargine/Lixisenatide",
   "pages": [
    {
     "brand": "Soliqua",
     "url": "https://omnirx.org/medicines/soliqua"
    }
   ],
   "labelSentence": "SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%224bba538b-cf7c-4310-ae8f-cb711ed21bcc%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Sanofi Patient Connection",
     "url": "https://omnirx.org/assistance/sanofi-patient-connection",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medications Available: medicines supported by Sanofi Patient Connection",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tirzepatide",
   "pages": [
    {
     "brand": "Mounjaro",
     "url": "https://omnirx.org/medicines/mounjaro"
    }
   ],
   "labelSentence": "MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220818426a-53eb-4db7-9609-bbae1e7a3964%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Mounjaro Savings (via Lilly)",
     "url": "https://omnirx.org/assistance/mounjaro-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Liraglutide",
   "pages": [
    {
     "brand": "Victoza 3-Pak",
     "url": "https://omnirx.org/medicines/victoza-3-pak"
    }
   ],
   "labelSentence": "... to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220ba917f7-b974-4364-a745-7494ecae3e73%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Metformin HCl",
   "pages": [
    {
     "brand": "Metformin HCl",
     "url": "https://omnirx.org/medicines/metformin-hcl"
    }
   ],
   "labelSentence": "Metformin Hydrochloride Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2206ade2e1-5981-4e3d-b7e9-7ff083eb4551%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Mifepristone",
   "pages": [
    {
     "brand": "Korlym",
     "url": "https://omnirx.org/medicines/korlym"
    }
   ],
   "labelSentence": "... to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22542f3fae-8bc8-4f00-9228-e4b66c9ad6a9%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}